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The Schlafen (SLFN) Family
The Schlafen (SLFN) family of genes, which is limited to mammals,
was initially discovered in mice by Schwarz et al., investigating the
T cell lineage, regulating differentiation and in some instances ablat-
ing growth [1]. In particular, overexpression of SLFN1 resulted in
a cell cycle arrest at the G0/G1 stage. Therefore, the family had been
named Schlafen, which is translated from German as “to sleep” [1].
Subsequent studies have classified the SLFN family into three distinct
subgroups based on gene/protein size and domain homology [2,3].
Ten mouse and six human SLFN genes have been identified to date
(Figure 1) [4]. All 10 mouse SLFN proteins possess a core region
containing a unique “slfn box” motif with an unknown function.
Subgroups II and III contain an extra domain at the C-terminus of
the slfn box, conserved by the flanking five amino acid signature (Ser-
Trp-Ala … -Asp-Leu) ‘SWA … DL’ which appears to be SLFN
specific. This was discovered in early characterization of the SLFN
family with SLFN3 and SLFN4 (members 3 and 4) possessing a 200
amino acid sequence not found in those in subgroup I [1]. Adjacent to
the slfn box is the ‘ATPases associated with diverse cellular activities’
(AAA) domain. Based on protein homology studies, theAAAmotif is
thought to function similarly to classical AAA domains with the role
of ATP/GTP binding in the course of DNA and RNAmetabolism and
therefore playing a fundamental role in the production and function of
SLFN proteins [5,6]. Another protein was discovered with significant
similarity to those in subgroup II, extending a further 400 amino acids
towards the C-terminus terminal tail. The sequence was aligned by
BLAST and the first 570 amino acids were homologous to SLFNs 3
and 4 while the remainder was unique to named SLFN8 leading to the
classification of the final SLFN subgroup, III [2]. Additional homo-
logous genes were identified as SLFN5, SLFN9, SLFN10 and
SLFN14, whereby the last two coding exons correspond to this unique
subgroup. NCBI conserved domain database (CDD) searches
revealed significant homology of subgroup III specific extension to
motifs typical in superfamily I of RNA/DNA helicases which are
known to mediate DNA and RNA metabolism [2]. The same char-
acterization method applies to the human-specific SLFN genes with
the absence of any subgroup I members and structural difference in
SLFN12L (SLFN12-LIKE). Notably, SLFN5 and SLFN14 are the only
SLFN family genes present in both human and mouse. The predicted
transcript of SLFN12L is of a similar length to those in subgroup III;
however, it also encompasses sequences which are unaccounted for
and based on this structural analysis, has not yet been assigned
a subgroup. According to length and homology, SLFN14 belongs to
subgroup III (Figure 1) [7]. The recently discovered crystal structure
of rat SLFN13 (related to human SLFN13 and mouse SLFN8)
N-domain gives a functional insight into its ability to cleave RNA
acting as an endoribonuclease in inhibiting protein synthesis [8].
Importantly, SLFN13 is the closest paralogue for SLFN14 (44%
identity and 61% similarity).
SLFN14 in mice is located on chromosome 11 and comprised of
five coding exons and in humans is on chromosome 17 with four
coding exons [9]. SLFN genes are highly conserved throughout the
mammalian species and are located in regions with other genes attri-
butable to T-cell and macrophage development [1]. Early mouse
knock-out studies investigating the role of SLFN1 in the immune
response showed no phenotype, suggesting potential functional redun-
dancy or minimal contribution of some members in the process [9].
The precise mechanisms of how some of the specific members of the
SLFN family cause human disease is still unclear.
SLFN14 Mutations in Patients with Platelet Disorders
and Bleeding
Platelet function disorders are associated with excessive bleeding
and with the advent of next-generation sequencing (NGS) including
whole exome sequencing (WES) the genetic impact of affected
individuals can be evaluated. Initially, three extended families
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were investigated in the Genotyping and Phenotyping of Platelets
Study, with three heterozygous single nucleotide variations in
SLFN14 resulting in missense mutations of consecutive amino
acids in the AAA domain [10]. The following year, an additional
family was discovered with another missense mutation in the same
region (R223W) and in 2019, Saes et al., reported a further patient
with an alternative base change at nucleotide c.657 yet still result-
ing in the K219N mutation (Table I and Figure 1) [11,12]. All four
mutations were inherited in an autosomal dominant fashion
whereby amino acid changes are conserved across all mammalian
species, except for V220D. The R223W variant is the only variant
out of these families to be reported on gnomAD (genome aggrega-
tion database) with a frequency of 6.5e-6. This highlights variant
rarity amongst different populations and confinement to the
families described. All individuals had macrothrombocytopenia,
characterized by a reduced platelet count (below 150x109/L) and
enlarged platelets suggesting this is a typical feature of SLFN14
related thrombocytopenia. Patients from the three initial families
showed a platelet function defect with impaired aggregation to
ADP, protease-activated receptor-1 (PAR-1) and Collagen and
reduced ATP secretion from dense granules after PAR-1 stimula-
tion [10]. Platelet aggregation was not stated for the cases in family
D or E but an unspecified secretion defect in the latter case was
reported [12]. The proband in family A was 31 years of age at the
time of measurement and had experienced severe cutaneous bruis-
ing, prolonged bleeding from wounds and menorrhagia [10]. These
symptoms were consistent across the three generations and are all
typical of moderate thrombocytopenia. The proband in family
B was 35 years old and had a history of spontaneous epistaxis;
her mother was also recruited but had not experienced any prior
bleeding tendencies [10]. Family C index case was 3 years old at
the time, displayed a very low platelet count and reported easy
bruising since birth [10]. Patients with variant R223W also
reported bleeding symptoms after dental surgery and mild menor-
rhagia, typical of thrombocytopenia [11]. Individual history for the
patient in family E was not detailed in publication however the
patient was recruited to the study based on bleeding tendency so,
therefore, is likely to be similar to those with the same muta-
tion [12].
All patients in these reported families were heterozygous for the
mutations and therefore phenotypically defined by platelet-type bleed-
ing disorder 20 (BDPLT20) which is specific to heterozygous muta-
tions in the SLFN14 gene. The absence of homozygous patients in the
families suggests the mutant allele in each variant group has signifi-
cant influence over the wild type. Indeed, heterozygous SLFN14
protein expression was reduced by 65%-80% when compared to
controls and in platelet spreading assays there is a reduction of
proplatelet extensions from developing megakaryocytes [10,11].
This apparent dominant negative effect on overall protein expression
can impact thematuration ofmegakaryocytes, affecting differentiation
and production of fully functional platelets [10,11]. In order to deci-
pher the role of SLFN14 in platelet biogenesis, it has been demon-
strated that SLFN14 acts as an endoribonuclease in controlling gene
expression [13,14]. SLFN14 is strongly overexpressed in rabbit
Figure 1. Schematic representation of the pro-
tein structure encoded by the SLFN family of
genes, highlighting domains and regions in both
mus musculus and homo sapiens.‘slfn’ box is
unique to SLFN proteins and function remains
unknown. The AAA domain is responsible for
DNA and RNA metabolism and the SWADL
region, again believed to be SLFN specific, is
a sequence flanked by SWA and DL amino
acids. The helicase regions at the C-terminal end
of the protein are known to mediate DNA and
RNA metabolism. The involvement of muta-
tions and thrombocytopenia within the AAA
domain of the SLFN14 protein remains unclear.
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reticulocyte lysate where it is one of the major ribosome-associated
proteins [13]. SLFN14 also binds to ribosomes in different model cell
lines [14]. Upon binding, SLFN14 cleaves ribosomal RNA and ribo-
some-associated messenger RNA resulting in ribosomal degradation
and disrupting translation [13,14]. Endoribonucleases mediate effec-
tive mechanisms in regulating gene expression; however, mutant
variants of ribosome-related proteins, such as SLFN14, may cause
errors in ribosome homeostasis and subsequent hematopoietic lineage
dysfunction [15,16]. For this reason, we can hypothesize that SLFN14
contributes to improper platelet formation from the disrupted transla-
tion of their precursors, megakaryocytes, which then results in an
inherited thrombocytopenia [14]. Given the structural similarity of
SLFN13 to other subgroup III genes (such as SLFN14) and the recent
report on SLFN13’s role as an endoribonuclease it seems plausible to
hypothesise that SLFN14 may be impacting megakaryocyte differen-
tiation and platelet synthesis by also acting as an endoribonuclease,
inhibiting translation and preventing complete protein synthesis
within the hematopoietic lineage [8].
It is only with the help of new genetic approaches over recent
years, that inherited thrombocytopenias with previously unknown
causes can now be attributed to single genetic defects. This not
only allows for expanding knowledge within the field of genetics
and hematological disorders but also provides patients with
a clear diagnosis and a plan for tailored clinical management.
Main Findings
● Mutations in SLFN14 cause inherited macrothrombocytopenia
characterized by enlarged platelets and moderate to severe
bleeding phenotypes.
● Three out of the five families with SLFN14 genetic variants show
reduced aggregation to agonists ADP, PAR-1 and Collagen,
decreased ATP secretion and dominant inheritance pattern.
● Endoribonucleolytic activity of SLFN14 contributes to platelet
formation by regulating translation process during their
maturation.
● The exact role of SLFN14 in platelet biogenesis and how
mutations within its AAA domain contribute to inherited
thrombocytopenia remain to be explored.
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